Literature DB >> 25135059

GFR may not accurately predict aspects of proximal tubule drug handling.

T L Putt1, Stephen B Duffull, J B W Schollum, R J Walker.   

Abstract

PURPOSE: Dose modification in renal impairment has traditionally been based on changes in estimated glomerular filtration rate (eGFR; estimated by creatinine clearance). However, many drugs are eliminated by tubular anionic and cationic transport where changes in eGFR may not necessarily reflect changes in tubular function. This study investigated the relationship between GFR and renal tubular function with reference to drug handling by using accepted drug probes.
METHODS: Three drug probes, (51)Cr-EDTA, fluconazole, and pindolol, were administered to patients who had varying degrees of renal impairment. Blood sampling, assays, and a pharmacokinetic analysis were performed for all drug probes and endogenous urate. Measured GFR ((51)Cr-EDTA clearance; mGFR) was compared to tubular anionic transport (urate clearance), tubular reabsorption (fluconazole clearance), and tubular cationic transport (S-pindolol clearance).
RESULTS: A moderately strong association was demonstrated between the measured isotopic GFR and creatinine clearance (R(2) = 0.78). A moderate positive correlation was found between mGFR and proximal tubular anion transport and reabsorption (R(2) = 0.40-0.44, p < 0.0001). In contrast, cationic secretion correlated poorly with mGFR (R(2) = 0.11, p = 0.036).
CONCLUSIONS: Given that drug dosing schedules utilise eGFR values as the basis for modifying drug dosing, our results would suggest that a recommendation of a dose reduction according to eGFR alone should be treated with caution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25135059     DOI: 10.1007/s00228-014-1733-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Analytical validation for a series of marker compounds used to assess renal drug elimination processes.

Authors:  A J McLachlan; A S Gross; J L Beal; I Minns; S E Tett
Journal:  Ther Drug Monit       Date:  2001-02       Impact factor: 3.681

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 3.  Overview: renal physiology and pathophysiology of aging.

Authors:  R D Lindeman
Journal:  Am J Kidney Dis       Date:  1990-10       Impact factor: 8.860

4.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

5.  Determination of pindolol enantiomers in human plasma and urine by simple liquid-liquid extraction and high-performance liquid chromatography.

Authors:  J L Beal; S E Tett
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-09-18

6.  The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis.

Authors:  Rossini Botev; Jean-Pierre Mallié; Jack F M Wetzels; Cécile Couchoud; Otto Schück
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-31       Impact factor: 8.237

Review 7.  Renal physiology and pathophysiology of aging.

Authors:  R D Lindeman
Journal:  Contrib Nephrol       Date:  1993       Impact factor: 1.580

8.  Systematic comparison of four sources of drug information regarding adjustment of dose for renal function.

Authors:  Liat Vidal; Maya Shavit; Abigail Fraser; Mical Paul; Leonard Leibovici
Journal:  BMJ       Date:  2005-05-19

9.  Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

Authors:  A S Gross; A J McLachlan; I Minns; J B Beal; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 10.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more
  11 in total

1.  Diurnal and Long-term Variation in Plasma Concentrations and Renal Clearances of Circulating Markers of Kidney Proximal Tubular Secretion.

Authors:  Matthew B Rivara; Leila R Zelnick; Andrew N Hoofnagle; Rick Newitt; Russell P Tracy; Mario Kratz; David S Weigle; Bryan R Kestenbaum
Journal:  Clin Chem       Date:  2017-02-10       Impact factor: 8.327

2.  Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Authors:  Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster
Journal:  Br J Clin Pharmacol       Date:  2019-02-27       Impact factor: 4.335

3.  Association of Serum Uromodulin With ESKD and Kidney Function Decline in the Elderly: The Cardiovascular Health Study.

Authors:  Dominik Steubl; Petra Buzkova; Pranav S Garimella; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paolo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2019-05-22       Impact factor: 8.860

4.  A general empirical model for renal drug handling in pharmacokinetic analyses.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2017-05-10       Impact factor: 4.335

5.  Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Authors:  Pier Giorgio Cojutti; Manuela Lugano; Elda Righi; Giorgio Della Rocca; Matteo Bassetti; William Hope; Federico Pea
Journal:  Eur J Clin Pharmacol       Date:  2018-07-21       Impact factor: 2.953

6.  A Population Pharmacokinetic Model for 51Cr EDTA to Estimate Renal Function.

Authors:  Isabelle H S Kuan; Stephen B Duffull; Tracey L Putt; John B W Schollum; Robert J Walker; Daniel F B Wright
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

7.  Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.

Authors:  Tom N Lea-Henry; Jane E Carland; Sophie L Stocker; Jacob Sevastos; Darren M Roberts
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-22       Impact factor: 8.237

8.  Prediction of Kidney Drug Clearance: A Comparison of Tubular Secretory Clearance and Glomerular Filtration Rate.

Authors:  Yan Chen; Leila R Zelnick; Andrew N Hoofnagle; Catherine K Yeung; Laura M Shireman; Brian Phillips; Calder C Brauchla; Ian de Boer; Linda Manahan; Susan R Heckbert; Jonathan Himmelfarb; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2020-11-25       Impact factor: 10.121

9.  Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.

Authors:  Eisuke Booka; Chiyo K Imamura; Hiroya Takeuchi; Yasuo Hamamoto; Daisuke Gomi; Takuro Mizukami; Takashi Ichiyama; Kazunari Tateishi; Tsunehiro Takahashi; Hirofumi Kawakubo; Kenzo Soejima; Narikazu Boku; Yusuke Tanigawara; Yuko Kitagawa
Journal:  Gastric Cancer       Date:  2015-08-25       Impact factor: 7.370

10.  Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis.

Authors:  A Chapron; D D Shen; B R Kestenbaum; C Robinson-Cohen; J Himmelfarb; C K Yeung
Journal:  Clin Transl Sci       Date:  2017-07-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.